NHF’s QMS is ISO – 9001:2015 Certified · Government of Jamaica

An agency of the Ministry of Health & Wellness

NEW DRUG & MORE GENERIC LABELS ADDED TO NHF DRUG LIST

NEW DRUG & MORE GENERIC LABELS ADDED TO NHF DRUG LIST

ADDITIONS CONTRIBUTING TO LOW PRICE INCREASES & HIGHER COMPLIANCE

The Active Pharmaceutical Ingredient (API), Nicotinic Acid (prolonged release), used to treat patients with high cholesterol, and is an adjunct for diabetes, ischaemic heart disease and hypertension has been added to the NHFcard Drug List. The NHFcard subsidy for each 500 milligram tablet is $27.00 and for the 1000milligram tablet, the subsidy is $54.00. This brings the total number of active ingredients on the NHFcard Drug List to 190. Ten (10) new generic drug brands for existing APIs have also been added to the NHFcard Drug List.

Mr. Rae Barrett, CEO NHF, says, “The regular addition of new products to the market, including generic drugs, has contributed to relatively low price increases seen for the APIs on the NHFcard Drug List.” He says in the past two years the average subsidy rate for NHFcard drugs has declined by 5% to 57% of the patient’s cost for the prescription item. In addition he notes “more generic drugs on the market improves the availability and affordability of drugs and therefore assists patient compliance with their medication requirement.”

The new generic labels which have been added are Apo-Carvedilol (Carvedilol) tablets used in the treatment of ischaemic heart disease and hypertension, with subsidy of $4.58 per 6.25 milligram; Apo-Risperdone (Risperdone) used for the treatment of psychosis and major depression with a subsidy of $33.13 per milligram; Serenata (Sertraline) 50 milligram tablets used for treating major depression, with a subsidy of $32.77; Louten (Latanoprost) Eye Drops 0.005%, 2.5 millilitre used in the treatment of glaucoma with a subsidy of $1,852.50; Simva (Simvastatin) tablets used in the treatment of high cholesterol, and as an adjunct for diabetes, ischaemic heart disease and hypertension, with a subsidy of $24.87 per 10 milligram; Mitotax (Paclitaxel) injection with a subsidy of $3,182.40.

The labels added for treating asthma are: Beclosal Inhaler (Salbutamol & Beclomethasene) with a subsidy of $409.50; Beclocip Inhaler (Beclomethasone) with a subsidy of $325.66; Salvent Inhaler (Salbutamol) $149.97 and Salmetide Inhaler (Salmetrol Xina & Fluticasone) with a subsidy of $2,636.00 for 125 mcg and $2,937.23 for 250mcg.

An agency of the Ministry of Health & Wellness
NHF’s QMS is ISO – 9001:2015 Certified

National Health Fund The Towers,
6th Floor 25 Dominica Drive,
Kingston 5

(876) 906-1106 / (876) 906-4381

1-888-DIAL-NHF (342-5643)

[email protected]

National Health Fund © 2024. All Rights Reserved.